已收盘 02-06 16:00:00 美东时间
+0.270
+12.56%
Senti Biosciences, Inc. (Nasdaq: SNTI) announced that its CEO, Dr. Timothy Lu, will present at the Healthcare Conference Taipei 2026. The presentation on February 10, 2026, will highlight the company's Gene Circuit technology platform, pipeline progress, and strategic priorities, emphasizing partnership opportunities across investment, R&D, manufacturing, and clinical collaboration. Senti Bio, focusing on next-generation cell and gene therapies, ...
02-03 14:00
11,061,738 Shares of Common StockThis prospectus relates to the resale from time to time of up to 11,061,738 shares of common stock, par value $0.001 per share (the "Common Stock") of iBio, Inc. (the "Company" or
01-31 05:24
The latest update is out from Ibio ( ($IBIO) ). On January 8, 2026, iBio, Inc. ...
01-13 06:56
iBio (IBIO) on Friday announced a securities purchase agreement with existing institutional investors for a private placement financing to raise ~$26M. Shares were +16.17% pre-market to $2.73. The bio...
01-09 20:54
The financing was led by Frazier Life Sciences and included participation from other existing investors.iBio intends to use the net proceeds received from the offering to advance its preclinical cardiometabolic programs,
01-09 20:05
Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) stock increased by 19.2% to $1...
01-09 20:05
iBio, Inc. has entered into a securities purchase agreement for a $26 million private placement financing with healthcare-focused institutional investors to advance its preclinical cardiometabolic programs and extend its cash runway into 2028. Frazier Life Sciences led the offering, with Leerink Partners as lead placement agent. The company will use proceeds to develop key assets and support general corporate purposes.
01-09 12:00
iBio Inc. ($IBIO), iRobot ($IRBT), and Webuy Global ($WBUY) are the 3Penn...
2025-12-10 00:17
Shares of Texas-based biotech firm iBio ($IBIO) have climbed as high as 50% ove...
2025-12-09 21:57
iBio, Inc. (NASDAQ: IBIO) announced its participation in the 8th Annual Evercore Healthcare Conference from December 2–4, 2025, in Miami. Martin Brenner, DVM, Ph.D., CEO and CSO of iBio, will discuss the company’s next-generation obesity pipeline and present non-human primate data for IBIO-610, a potential first-in-class Activin E antibody, during a fireside chat on December 4 at 8:45 a.m. ET. Felipe Duran, iBio’s CFO, will be available for one-o...
2025-11-24 21:15